PACS Group (PACS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of Evelyn Dilsaver and Mark Hancock as Class II directors to serve until the 2029 annual meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PACS Group
- Q1 2026 revenue up 11.2%, net income up 184%, and 2026 EBITDA guidance raised to $605–$625M.PACS
Q1 202612 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.PACS
Proxy filing28 Apr 2026 - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 202527 Feb 2026 - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 20241 Feb 2026 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Offering 2.78M shares at $39.67 to repay debt; founders retain control; strong growth, high regulatory risk.PACS
Registration Filing29 Nov 2025 - Shareholders will vote on director elections, auditor ratification, and executive compensation matters.PACS
Proxy Filing25 Nov 2025 - Q3 2024 revenue up 29.8% year-over-year, but net income down amid higher costs and compliance issues.PACS
Q3 202420 Nov 2025